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B lymphocytes can respond rapidly to nonself-
antigens, yet even at mature stages of develop-
ment can be rendered tolerant if they encounter 
self-antigen  (Goodnow  et  al.,  2005).  How  B 
cells distinguish self from nonself has been ex-
plained in part by Bretscher and Cohn’s associa-
tive  recognition  (“two-signal”)  hypothesis 
(Bretscher and Cohn, 1970), which posits that B 
cells can only achieve activation after a second 
signal is delivered, the first being recognition of 
antigen by the BCR. Without this second signal, 
tolerance is induced. In response to T-dependent 
antigens,  activated  helper T  cells  provide  this 
second  signal.  In  a T-independent  type  1  re-
sponse, the second signal might come from the 
B cells’ Toll-like receptors (TLRs) recognizing 
conserved microbial motifs attached to the anti-
gen  (e.g.,  lipopolysaccharide;  Coutinho  et  al., 
1974). This model, however, fails to explain how 
T-independent type 2 (TI-2) responses occur, as 
TI-2 antigens require neither T cells (Mond et al., 
1995) nor recognition by known innate im-
mune receptors (Gavin et al., 2006), and can 
elicit antibody responses in cultures of single B 
cells (Nossal and Pike, 1984). Although we do 
not dispute contributory roles of innate immune 
receptors, cytokines, or accessory cells in ampli-
fying  their  responses  (Mond  et  al.,  1995; Vos   
et al., 2000; Hinton et al., 2008), TI-2 antigens 
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Autoreactive B lymphocytes first encountering self-antigens in peripheral tissues are nor-
mally regulated by induction of anergy or apoptosis. According to the “two-signal” model, 
antigen recognition alone should render B cells tolerant unless T cell help or inflammatory 
signals such as lipopolysaccharide are provided. However, no such signals seem necessary 
for responses to T-independent type 2 (TI-2) antigens, which are multimeric antigens 
lacking T cell epitopes and Toll-like receptor ligands. How then do mature B cells avoid 
making a TI-2–like response to multimeric self-antigens? We present evidence that TI-2 
antigens decorated with ligands of inhibitory sialic acid–binding Ig-like lectins (siglecs) are 
poorly immunogenic and can induce tolerance to subsequent challenge with immunogenic 
antigen. Two siglecs, CD22 and Siglec-G, contributed to tolerance induction, preventing 
plasma cell differentiation or survival. Although mutations in CD22 and its signaling ma-
chinery have been associated with dysregulated B cell development and autoantibody 
production, previous analyses failed to identify a tolerance defect in antigen-specific 
mutant B cells. Our results support a role for siglecs in B cell self-/nonself-discrimination, 
namely suppressing responses to self-associated antigens while permitting rapid “missing 
self”–responses to unsialylated multimeric antigens. The results suggest use of siglec ligand 
antigen constructs as an approach for inducing tolerance.
© 2010 Duong et al.  This article is distributed under the terms of an Attribu-
tion–Noncommercial–Share Alike–No Mirror Sites license for the first six months 
after the publication date (see http://www.jem.org/misc/terms.shtml). After six 
months it is available under a Creative Commons License (Attribution–Noncom-
mercial–Share Alike 3.0 Unported license, as described at http://creativecommons 
.org/licenses/by-nc-sa/3.0/).
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ence for sialoside ligands with the disaccharide sequence 
NeuGc2-6Gal (Collins et al., 2006a; Crocker et al., 2007), 
whereas Siglec-G, before this study, has had an unknown li-
gand specificity. Their disaccharide ligands represent terminal 
sugars commonly carried on N- and O-linked glycans of glyco-
proteins and are found on virtually all cells, including B cells 
(Crocker et al., 2007). It is well documented that CD22 binds 
to glycans on endogenous B cell glycoproteins in cis, and masks 
the ligand binding site from binding synthetic polymeric ligands 
(Hanasaki et al., 1995; Razi and Varki, 1998; Razi and Varki, 
1999; Collins et al., 2002; Han et al., 2005). Yet, CD22 is able 
to recognize native ligands on glycoproteins of apposing cells in 
trans, causing it to redistribute to the site of cell contact (Lanoue 
et al., 2002; Collins et al., 2004). Although mutations of the li-
gand binding domain of CD22 (Jin et al., 2002; Poe et al., 
2004) and ablation of enzymes involved in the synthesis of its 
glycan ligands (Hennet et al., 1998; Poe et al., 2004; Collins   
et al., 2006b; Ghosh et al., 2006; Grewal et al., 2006; Naito   
et al., 2007; Cariappa et al., 2009) document the importance of 
siglec ligands in the regulation of CD22 function, a unifying 
role for CD22 ligand interactions in B cell biology has not yet 
emerged (Crocker et al., 2007; Walker and Smith, 2008). 
Although less is known about the specificity of Siglec-G and 
its interaction with ligands, it is assumed that similar con-
cepts regarding cis and trans ligands will apply to the mod-
ulation of Siglec-G function (Hoffmann et al., 2007; Chen 
et al., 2009).
Because siglecs see sialylated glycans that are usually ab-
sent from microbes, with the notable exceptions of some 
pathogenic  microbes  (Crocker  et  al.,  2007;  Carlin  et  al., 
2009a), one possible role of siglecs is to discriminate self from 
nonself. Though CD22 and Siglec-G have been implicated 
to play roles in B cell tolerance, evidence has been indirect, 
inferred from the facts that they possess ITIMs able to recruit 
SHP-1 and dampen Ca2+ signaling (Otipoby et al., 1996; 
Sato et al., 1996; Nitschke et al., 1997; O’Keefe et al., 1999; 
Ding et al., 2007; Hoffmann et al., 2007). Hypomorphic or 
null alleles of CD22 and SHP-1 (Ptpn6) have been correlated 
with anti-DNA production and development of lupus ery-
thematosus (Shultz et al., 1993; O’Keefe et al., 1999; Mary   
et al., 2000). CD22 mutations also lead to increased in vivo 
B  cell  proliferation  and  turnover  (Otipoby  et  al.,  1996; 
Nitschke et al., 1997; Poe et al., 2004; Haas et al., 2006; On-
odera et al., 2008). However, studies designed to directly 
assess tolerance induction in antigen-specific CD22/ or 
SHP-1 mutant B cells found, paradoxically, a more robust 
tolerance relative to unmutated controls (Cyster and Good-
now, 1995; Cornall et al., 1998; Ferry et al., 2005). This sug-
gests that the autoimmune phenotypes of siglec and SHP-1 
null mutants could be caused by abnormal B cell selection 
and development rather than failure of tolerance. It is gener-
ally assumed that physical association of CD22 with the BCR 
will allow CD22 to exert a maximal inhibitory response (Pe-
zzutto et al., 1987; Doody et al., 1995; Lanoue et al., 2002; 
Courtney et al., 2009), but evidence to support this has been 
garnered only from in vitro experiments (Ravetch and Lanier, 
appear to have only two surprisingly simple properties, high 
molecular weight and ≥20 closely spaced BCR epitopes (Dintzis 
et al., 1976), and are thus unlikely to have innate receptors spe-
cialized for their recognition.
Alternatively, B cells might be capable of “missing self”–
recognition (Parish, 1996; Nemazee and Gavin, 2003) similar 
to that originally observed in NK cells (Kärre et al., 1986). In 
NK cell recognition, the decision to lyse a target cell depends 
on integration of opposing signals from activating and inhibi-
tory receptors (Lanier, 2008). Activating receptors trigger re-
cruitment  of  tyrosine  kinases  to  immunotyrosine  activating 
motifs of associated adapter molecules but are kept in check by 
inhibitory receptors recognizing classical MHC I molecules ex-
pressed on target cells (Lanier, 2008). Inhibitory receptors carry 
immunotyrosine  inhibitory  motifs  (ITIMs),  which  serve  as 
docking sites for phosphatases, such as SHP-1, that counteract 
activation (Ravetch and Lanier, 2000). Target cells that down-
regulate MHC I are lysed owing to unopposed activation, 
hence missing self–recognition.
Extrapolating from this model, we hypothesize that besides 
their BCR epitopes, self-antigens carry self-markers that can 
engage inhibitory receptors on B cells, preventing antiself TI-
2–like responses and rendering activation dependent on sec-
ond  signals.  The  concept  that  self-markers  might  facilitate 
self-tolerance was first suggested many years ago by Burnet 
and Fenner (1949) but has garnered little experimental sup-
port with respect to lymphocyte tolerance. According to our 
model, antigens that simultaneously cross-link the BCRs and 
inhibitory receptors should prevent or blunt B cell responses. 
Conversely, antigens that bind only the BCR and not inhibi-
tory receptors are predicted to elicit a TI-2 response, provided 
that they carry the appropriate number and spacing of epi-
topes. This missing self–model of self-/nonself-discrimination 
would explain why B cells constitutively express so many in-
hibitory receptors that recognize ubiquitous self-components, 
and why null mutations in those receptors or their signaling 
machinery can lead to autoantibody formation (Nishimura et al., 
1998; Pan et al., 1999; Ravetch and Lanier, 2000; Nemazee 
and Gavin, 2003).
In this study, we chose to test if self-/nonself-discrimination 
is regulated by self-markers through the roles of the sialic acid–
binding Ig-like lectins (siglecs) CD22 and Siglec-G in B cells. 
The siglec family consists of 9 members in mice and 13 mem-
bers in humans (for review see Crocker et al., 2007). In mice, 
mature B cells express CD22 (Siglec 2) and Siglec-G, which 
bind to host sialic acids carried on glycans of glycoproteins and 
glycolipids and have properties of inhibitory receptors. They 
carry  ITIMs  capable  of  recruiting  the  tyrosine  phosphatase 
SHP-1 and attenuating BCR signaling (Campbell and Klin-
man, 1995; Doody et al., 1995; Cornall et al., 1998). Mice car-
rying null mutations in either CD22 or Siglecg exhibit B cell 
hyperactivity, variable responses to T-independent antigens, and 
a  tendency  toward  autoantibody  formation  (O’Keefe  et  al., 
1996; Otipoby et al., 1996; Sato et al., 1996; Nitschke et al., 
1997; Cornall et al., 1998; O’Keefe et al., 1999; Ding et al., 2007;   
Hoffmann et al., 2007). Mouse CD22 exhibits a strong prefer-JEM VOL. 207, January 18, 2010 
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and  together  bind  native  sialosides  containing  both  the 
NeuGc2-6 and NeuGc2-3 linkages to Gal1-4GlcNAc found   
as terminal sequences on glycans of most, if not all, mouse cells.
In vivo responses to TI-2 conjugates carrying siglec ligands
To see if incorporating siglec ligands into TI-2 antigen affects 
B cell in vivo responses, PA was conjugated with nitrophenol 
(NP) hapten and one of two glycans found to be ligands of 
CD22 and Siglec-G. We selected the natural sialoside NeuGc 
and the high affinity siglec ligand bNeuGc to ensure that ad-
equate competition with cis ligands would be achieved. As an 
immunogenic control, a corresponding conjugate (NP–PA) 
was  prepared  with  a  glycan  lacking  sialic  acid  (Gal1-
4GlcNAc). The resulting polymers contained 200 NP hap-
tens and 400 glycan moieties (Fig. 2 A).
Because haptens appropriately displayed on high molecu-
lar weight PA should behave as TI-2 antigens (Dintzis et al., 
1976), we anticipated that NP–PA would elicit an anti-NP 
antibody response, whereas the response to NP–PA–NeuGc 
and NP–PA–bNeuGc might be blunted by recruitment of si-
glecs to the BCR binding the antigen. As anticipated, robust 
IgM and IgG3 responses against NP were detected in mice 
immunized with NP–PA (Fig. 2, B and C). In contrast, NP–
PA–bNeuGc failed to induce a significant anti-NP response 
(Fig. 2 B) and NP–PA–NeuGc elicited a significantly reduced 
response (Fig. 2 C). The results indicated that presentation of 
siglec ligands reduced or prevented the antibody response to 
the antigen, and the extent of the reduction correlated with 
their affinity to CD22 and Siglec-G.
Contributions of siglecs in down-regulation  
of antigen responses by native glycan ligands
As shown in Fig. 1, both Siglec-G and CD22 combine for   
optimal binding of the native ligand (NeuGc) incorporated 
into the NP–PA–NeuGc construct. To assess the roles of 
these siglecs in the altered response, we compared NP anti-
body responses to NP–PA–NeuGc and NP–PA in CD22/, 
Siglecg/, and wild-type mice (Fig. 3). NP–PA–NeuGc elic-
ited a significantly reduced response compared with NP–PA 
in wild-type mice. CD22/ mice also responded poorly to 
sialylated  compound,  though  the  response  to  unsialylated 
conjugate was slightly lower than in wild-type mice (Fig. 3, 
A and B), consistent with previous studies (Otipoby et al., 
1996; Nitschke et al., 1997). In contrast, the presence of 
sialylated glycans completely failed to reduce the response in 
Siglecg/ mice (Fig. 3 C). Thus, consistent with the binding 
data (Fig. 1 B), Siglec-G rather than CD22 is predominately 
responsible for the reduced response to natively sialylated 
conjugate under the conditions of immunization used in 
this study.
Tolerance induction by TI-2 antigen carrying siglec ligands
We considered three possibilities for the effects of antigen si-
alylation on B cell response: (1) it dampened the response, (2) it 
dampened the response and actively induced tolerance, and 
(3) it rendered antigen invisible. The robust immunogenicity 
2000; Lanoue et al., 2002; Tedder et al., 2005; Courtney 
et al., 2009). In this paper, we show in wild-type mice with 
unaltered B cell selection and development that decorating a 
TI-2 antigen with siglec ligands not only prevents its immuno-
genicity but can also tolerize B cells to subsequent challenges 
with the unsialylated, immunogenic form. The results suggest 
that one function of B cell inhibitory receptors like siglecs is 
to assist B cells in distinguishing self from nonself.
RESULTS
Specificity of CD22 and Siglec-G for multivalent sialosides 
linked to polyacrylamide (PA)
Because our goal was to design copolymers of siglec ligands 
and a TI-2 antigen that would recruit siglecs to the hapten-
specific BCR, we characterized highly multivalent sialylated 
glycans linked to PA for their ability to compete with cis li-
gands and bind to CD22 and Siglec-G on native B cells. We 
and others previously showed that synthetic trans ligands of 
CD22 (NeuGc2-6Gal) compete poorly with endogenous 
cis ligands unless they were displayed on highly multivalent 
polymers and included hydrophobic substituents at the 9 po-
sition that increase affinity (Razi and Varki, 1998; Collins 
et al., 2002; Collins et al., 2006a). Therefore, we evaluated 
binding of highly multivalent PA conjugates (1,000 kD) car-
rying sialosides (n ≈ 400) and biotin tags to facilitate their de-
tection. Each was analyzed for its binding to B cells from 
wild-type, CD22-deficient, Siglec-G–deficient, and CD22/
Siglec-G double-deficient mice (Fig. 1). The PA–sialosides 
with NeuAc2-6Gal1-4GlcNAc–containing glycans showed 
no binding to mouse B cells, consistent with the known 
preference of mouse CD22 for NeuGc2-6Gal1-4GlcNAc 
(NeuGc; Fig. 1, A and D; Crocker et al., 2007). The conju-
gate containing the preferred native ligand of CD22, NeuGc, 
was bound well by wild-type cells (Fig. 1 B). Surprisingly, 
however, binding to this glycan by both CD22/ and   
Siglecg/ single-deficient B cells was also significantly re-
duced, whereas CD22/;Siglecg/ double-deficient B cells 
completely failed to bind, indicating that both siglecs con-
tribute to binding (Fig. 1 B). Thus, the glycan previously de-
scribed as the natural ligand for CD22 (Pezzutto et al., 1987; 
Collins et al., 2002; Blixt et al., 2003; Crocker et al., 2007) is 
also a ligand of Siglec-G, and both siglecs are required for 
optimal binding of this ligand. Similarly, the PA–9-biphenyl-
acetyl-NeuGc2-6Gal1-4GlcNAc (PA–bNeuGc) conjugate, 
previously shown to have high affinity for mouse CD22 
(Collins et al., 2006a), was bound strongly by B cells, and 
whereas binding to CD22 was dominant, both CD22 and 
Siglec-G contributed to the association (Fig. 1 C). B cells from 
CD22/;Siglecg/ mice exhibited residual binding to PA–
bNeuGc (6%), suggesting that an additional receptor might 
also recognize this ligand. Importantly, binding to wild-type 
B cells of sialoside with NeuGc in 2-3 linkage to Gal1-
4GlcNAc was also observed (Fig. 1 E). However, in this case 
binding was exclusively caused by Siglec-G, for there was 
little change in binding to CD22/ B cells. We conclude that 
Siglec-G and CD22 have distinct and overlapping specificities, 176 Missing self–recognition by B cells | Duong et al.
ligand  NP–PA–bNeuGc  and  then  subsequently  challenged 
with NP–PA. Remarkably, a single dose of NP–PA–bNeuGc 
rendered mice tolerant to NP–PA for at least 1 mo, as indi-
cated by the near absence of anti-NP responses after two chal-
lenges with the unsialylated antigen 14 and 31 d later (Fig. 4 B). 
Control experiments showed that PA–bNeuGc lacking NP 
had no negative effect on the subsequent NP response to 
NP–PA and that tolerance induction by NP–PA–bNeuGc 
took about 2 wk to be fully established (Fig. S1, A and B). 
Furthermore, conjugates carrying identical amounts of Gal1-
4GlcNAc (nonsiglec binding) and decreasing amounts of NP 
did not induce tolerance to NP but instead simply showed de-
creasing potency in eliciting an initial anti-NP response (Fig. 
S2), thus ruling out the trivial possibility that glycan modifica-
tions hinder recognition of NP because of steric interactions. 
These results further supported the notion that antigen si-
alylation did not prevent its recognition by B cells but led to a 
distinct biological response. We conclude that attachment of 
high affinity siglec ligands to TI-2 antigen promoted antigen-
specific tolerance rather than immunity, whereas a lower affin-
ity ligand significantly blunted but did not always completely 
prevent the antibody response.
To test the robustness of the tolerance, we asked if nonspe-
cific activators of inflammation could prevent tolerance induc-
tion by sialylated antigen. Accordingly, mice were challenged 
of NP–PA–NeuGc in the absence of Siglec-G recognition 
showed that the poor response elicited to this compound in 
wild-type and CD22/ mice was not caused by hapten in-
accessibility, arguing against the third possibility. To further 
investigate the possibility of tolerance induction, a series of 
experiments  was  performed  whereby  mice  previously  in-
jected with sialylated NP conjugates were subsequently chal-
lenged with immunogenic NP–PA.
Because NeuGc-carrying NP conjugates appeared to 
suppress anti-NP responses less efficiently than those with 
bNeuGc, we first generated additional conjugates with similar 
amounts of native siglec ligand but less NP, and tested them 
in C57BL/6 mice for their ability to elicit anti-NP responses 
and to modulate a secondary challenge with NP200–PA. Op-
timal results were obtained with NP65–PA–NeuGc400. Re-
markably, the sialylated antigen not only elicited significantly 
lower primary IgM and IgG3 responses than the correspond-
ing immunogenic NP65–PA control but also led to reduced 
responses upon subsequent immunization with unsialylated 
NP200–PA antigen (Fig. 4 A). The results demonstrated the 
ability of natively sialylated TI-2 antigen to suppress antibody 
responses and to promote tolerance, provided that the BCR 
signal did not outweigh siglec-mediated inhibition.
Even more striking biological effects were seen in mice in-
jected with the conjugate containing the higher affinity siglec 
Figure 1.  Binding analysis of various sialylated PA–glycan conjugates to wild-type compared with siglec mutant B cells. Results are represen-
tative of three independent experiments. (A–E) B cells of the indicated genotypes were stained with biotinylated PA conjugated with the following gly-
cans: (A) NeuAc2-6Gal1-4GlcNAc, (B) NeuGc, (C) bNeuGc, (D) NeuAc2-3Gal1-4GlcNAc, and (E), NeuGc2-3Gal1-4GlcNAc. Binding was revealed 
using fluorescent streptavidin. Background staining by streptavidin alone is shown in gray. (F) Chemical structures of the NeuGc-containing sialosides.JEM VOL. 207, January 18, 2010 
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ment with NP–PA–bNeuGc, both strains generated a strong 
IgM response upon subsequent immunization with NP–PA 
(Fig. 4, C and D, top). However, in both mutants subsequent 
IgG3 responses to NP–PA were still notably deficient. Over-
all, these data indicated that tolerance induced by sialylated 
antigen was impaired in CD22/ and Siglecg/ mice, and 
therefore was partly dependent on both CD22 and Siglec-G. 
A preliminary experiment immunizing CD22/;Siglecg/ 
mice gave similar results to the single mutants (Fig. S3), sug-
gesting that there may be another siglec on B cells compensat-
ing for their function (see Discussion).
In vivo visualization of the B cell response
To follow cellular aspects of anti-NP B cell responses in vivo, 
splenic NP-specific B cells were isolated from quasimonoclo-
nal (QM) anti-NP BCR-transgenic mice (Cascalho et al., 
1996), transferred to Rag1/ hosts, and challenged with con-
jugates given i.p., and recipient splenocytes were analyzed 7 d 
later. Mice were administered BrdU throughout to label cells 
that proliferated during this period. Significant differences in 
proliferation were seen in response to NP–PA compared with 
NP–PA–bNeuGc (P = 8.5 × 106; Fig. 6 A, left two columns). 
In recipients immunized with NP–PA, 90% of B220+ cells 
were BrdU labeled during the 7-d period, whereas prolifera-
tion was lower in response to NP–PA–bNeuGc (50%), PA–
bNeuGc (20%), or saline (22%; Fig. 6 C). Similar results were 
obtained when QM B cells were transferred along with non-
transgenic B cells or transferred into unirradiated, RAG-suf-
ficient hosts (Fig. S4 and not depicted). A large fraction of the 
BrdU+ cells in recipients challenged with NP–PA appeared to 
be follicular phenotype B cells, as they expressed CD23 and 
IgD. Importantly, the generation of NP-specific plasma cells 
and serum antibody was robust in NP–PA–immunized mice but 
extremely poor in other treatment groups (Fig. 6, B and D). 
The increased proliferative response to NP–PA–bNeuGc, 
compared with PA–bNeuGc or saline challenge, was attrib-
utable to NP recognition but was not correlated with an anti-
body response. We conclude that tolerance induction to 
sialylated antigen is associated with suboptimal B cell prolifer-
ation without plasma cell differentiation and likely death of 
abortively activated cells.
Responses of Bcl2-transgenic B cells
To assess the possibility that NP–PA–bNeuGc promoted tol-
erance through an apoptotic mechanism, we challenged mice 
carrying the E-Bcl2-22 transgene (Bcl2 Tg; Strasser et al., 
1991), which have enforced Bcl2 expression in B cells and 
are known to have impaired peripheral B cell tolerance (Lang 
et al., 1997). NP–PA–bNeuGc challenge failed to prevent 
Bcl2 Tg mice from making a subsequent response to NP–PA, 
whereas similarly treated wild-type mice were tolerized (Fig. 7, 
condition C). These data suggest that NP–PA–bNeuGc 
challenge led to apoptosis of NP-reactive B cells in wild-type 
mice but not in Bcl2 Tg mice. It is noteworthy that enforced 
expression of Bcl2 did not permit B cells to respond by anti-
body production to NP–PA–bNeuGc (condition A), whereas 
with NP–PA–bNeuGc mixed with Ribi, an adjuvant containing 
TLR4 ligand and other proinflammatory signals. This treatment 
was only able to rescue IgM and IgG3 responses to 10–20% of 
the response to NP–PA given with Ribi (Fig. 5 A), though it 
also rescued subsequent responses to rechallenge with NP–PA 
18 d later (Fig. 5 B). Thus, although inflammatory signals pro-
vided by adjuvant overrode tolerance, siglec ligands could still 
significantly suppress their amplification of the TI-2 response.
Analysis of the siglec dependence revealed that both CD22 
and Siglec-G were required for optimal induction of toler-
ance by NP–PA–bNeuGc. Even though neither CD22/ 
nor Siglecg/ mice made an anti-NP response to initial treat-
Figure 2.  Design of sialylated and unsialylated TI-2–like conjugates 
and comparison of initial antibody responses elicited in C57BL/6 
mice. (A) Structure of immunogenic and tolerogenic conjugates. Shown 
schematically are PA conjugates carrying both NP and the nonsiglec-bind-
ing carbohydrate Gal1-4GlcNAc (NP–PA), compared with the conjugates 
NP–PA–NeuGc or NP–PA–bNeuGc. (B and C) Mice were immunized 7 d 
previously with 20 µg of the indicated conjugates in PBS. Unless otherwise 
stated, the antigen dose given in all experiments of this study was 20 µg in 
PBS. Results shown are representative of at least three independent ex-
periments. All statistical tests given used the two-tailed Student’s t test. 
Means + SD are shown. *, P < 0.05; ***, P < 0.005. (B) Antibody response to 
NP–PA–bNeuGc (+) versus NP–PA (; n = 4/group). (C) Antibody response 
to NP–PA–NeuGc (+) versus NP–PA (; n = 7/group).178 Missing self–recognition by B cells | Duong et al.
jugate without NP failed to induce phosphorylation, except 
perhaps in CD22 (lanes 6 and 7), but as shown in Fig. S1, 
this had no effect on subsequent responses to NP. CD22 
immunoprecipitates revealed, as expected, that upon activation 
with conjugate a fraction of SHP-1 was bound (Fig. 8 E, lanes 
2 and 4). However, the relative levels of associated SHP-1 were 
similar in both NP–PA– and NP–PA–bNeuGc–stimulated 
cells  and  were  also  significant  in  PA–bNeuGc–stimulated 
cells, despite the differences in overall tyrosine phosphoryla-
tion. Phosphorylation of Y531 on CD19 is known to recruit 
PI3K activity leading to Akt activation and attendant S473 
phosphorylation (Tuveson et al., 1993; Otero et al., 2001; 
Wang et al., 2002). At 5 min after NP–PA stimulation, CD19 
(Y531) and Akt (S473) phosphorylation were elevated (Fig. 
8, F and G, lane 2), whereas in NP–PA–bNeuGc–challenged 
cells no increased phosphorylation was seen (lane 4). This in-
dicated that the most striking effect of BCR/Siglec coligation 
was suppression of CD19 phosphorylation and downstream 
PI3K/Akt activation rather than SHP-1 recruitment alone. 
Thus, sialylated antigen induced more CD22 phosphoryla-
tion,  suppressed  early  activation  signals,  and  directly  sup-
pressed antigen-specific B cell proliferation in vitro.
DISCUSSION
With their high molecular weights and multimeric arrays of 
identical  epitopes,  most  host  cell  surfaces  and  fragments 
thereof are potential TI-2 antigens, but rather than inducing a 
response, host cell-surface antigens are strongly tolerogenic 
for mature B cells (Russell et al., 1991; Murakami et al., 1992). 
An important difference from immunogenic TI-2 antigens 
it rescued a subsequent response to NP–PA. These data show 
that NP-specific B cells protected from apoptosis neither re-
sponded to nor were tolerized by sialylated conjugate, indi-
cating  that  B  cell  tolerance  involved  both  apoptotic  and 
nonapoptotic mechanisms.
In vitro responses to TI-2 conjugates  
with or without siglec ligands
To further probe the effects of antigen sialylation on B cell 
responses, NP–PA, NP–PA–bNeuGc, and PA–bNeuGc were 
compared for their abilities to bind and to activate NP-
specific B cells. Both NP and bNeuGc made important inde-
pendent contributions to overall binding, which was enhanced 
with conjugates carrying both ligands (Fig. 8 A). In response 
to NP–PA challenge in vitro, NP-reactive splenic B cells mo-
bilized Ca2+ (Fig. 8 B) and proliferated (Fig. 8 C), whereas 
they responded poorly to NP–PA–bNeuGc (Fig. 8, B and 
C). PA–bNeuGc had no effect on B cell proliferation in vitro 
(unpublished data). Thus, despite improving binding to B 
cells, sialylated antigen suppressed NP-specific B cell respon-
siveness in vitro.
Tyrosine phosphorylation analysis of NP-specific B cells 
stimulated  with  tolerogenic  compared  with  immunogenic 
NP conjugates revealed that sialylation altered both overall 
and CD22-specific phosphorylation (Fig. 8, D–G). NP–PA 
stimulated robust tyrosine phosphorylation of many substrates 
(Fig. 8 D, lane 2), whereas NP–PA–bNeuGc triggered a 
comparatively reduced overall tyrosine phosphorylation (lane 4), 
with the notable exception of CD22, which was more 
strongly phosphorylated (Fig. 8 E, lane 4 vs. 2). Control con-
Figure 3.  Serum anti-NP responses to unsialylated (; NP–PA) or natively sialylated (+; NP–PA–NeuGc) compounds. (A–C) Responses of (A) 
wild-type, (B) CD22/, and (C) Siglecg/ mice. Anti-NP titers were assessed on days 7 and 14 as indicated. (top) IgM anti-NP titers; (bottom) IgG3 anti-
NP titers. Each point represents the response of an individual mouse of the indicated genotype. Results shown are representative of at least two indepen-
dent experiments. Horizontal bars represent means. *, P < 0.05; and ***, P < 0.005 using the two-tailed Student’s t test. n.s., not significant.JEM VOL. 207, January 18, 2010 
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may be that host tissues are sialylated and can engage siglecs. 
Indeed, sialic acids have been estimated to be present on cell 
surfaces at concentrations of >10 mM (Collins et al., 2004). In 
an in vitro model of B cell reactivity to cell-surface antigen, 
Lanoue et al. (2002) demonstrated that expression of CD22 
ligands on cells could suppress induction of B cell co-stimula-
tory molecules through a CD22-dependent pathway, pre-
sumed to result from redistribution of CD22 to the site of cell 
contact by trans ligands on the antigen-presenting cell (Collins 
et al., 2004). We find that when TI-2 antigens are sialylated it 
renders them tolerogenic or nonimmunogenic in vivo, and 
present genetic evidence that both CD22 and Siglec-G con-
tribute to both suppression of immune responses and tolerance 
induction. Previous studies have shown that coengagement of 
CD22 and the BCR can suppress early B cell signal transduc-
tion and blunt activation (Lanoue et al., 2002; Tedder et al., 
2005; Courtney et al., 2009), but experiments designed to 
directly assess B cell tolerance in the presence and absence of 
CD22 or its downstream signaling components failed to re-
veal a defect in tolerance induction (Cyster and Goodnow, 
1995; Cornall et al., 1998; Ferry et al., 2005). The primary 
difference in our studies is the analysis of responses to TI-2 
antigens conjugated to siglec ligands to introduce missing self. 
To our knowledge, the present studies are the first to clearly 
demonstrate that siglecs facilitate B cell tolerance, as opposed to 
simply blunting antigen recognition, and suggest a general par-
adigm for the role of B cell siglecs in regulating BCR response 
to antigens in the context of distinguishing self from nonself.
In this study we have focused on siglecs and sialic acid–con-
taining glycans as self-markers. Although CD22 is highly spe-
cific for 2-6 sialosides (Crocker et al., 2007), it is notable that 
Siglec-G recognizes both 2-3– and 2-6–linked sialosides 
(Fig. 1). Thus, the specificities of these two siglecs are comple-
mentary and together cover the most common sequences 
found on cell-surface glycans, providing a broad basis for self-
recognition with two siglecs. Although siglecs are a rapidly 
evolving family (Crocker et al., 2007), CD22 expression is 
conserved in mammals, and human B cells express Siglec-10, 
an orthologue of Siglec-G, as well as Siglec-5 (Crocker et al., 
2007; Yamanaka et al., 2009). The specificity of these three 
siglecs combined cover all the major sialoside sequences 
expressed on human cells (Crocker et al., 2007). Thus, al-
though the ligands recognized by the specific human and mouse 
B cell siglecs have evolved, the ligand specificities cover the 
major sialoside sequences expressed as self-markers on cells.
Figure 4.  Analysis of tolerance induction by the sialylated antigens 
NP–PA–NeuGc and NP–PA–bNeuGc, and responses in siglec- 
deficient mice. (A–D) Functional assay of in vivo tolerance induction. 
Results shown are representative of at least two independent experiments. 
(A) Mice (n = 4/group) were challenged with NP65–PA–NeuGc on day 0 and 
rechallenged with NP200–PA on day 17. IgM and IgG3 antibody levels were 
assessed at the indicated time points. Control mice received either NP65–
PA on day 0 and were rechallenged with NP200–PA as in the experimental 
group, or received just NP200–PA without pretreatment (green lines). #, a 
significant reduction in NP65–PA–NeuGc–pretreated mice at 7 d after 
challenge with NP200–PA (P = 8.84 × 105) compared to nonpretreated 
animals at 7 d after NP200–PA challenge (green line). (B) Mice (n = 4/
group) were challenged with NP–PA–bNeuGc on day 0 and rechallenged 
with NP–PA on days 14 and 31. Control mice received NP-Ficoll on day 0 
and were rechallenged with NP–PA as in the experimental group. (C and 
D) Tolerance induction in siglec-deficient mice. Serum IgM and IgG3 anti-
NP responses of mice that were primed on day 0 with either NP–PA–
bNeuGc or NP–PA and boosted on days 17 or 18 with NP–PA. (C) 
Responses in CD22/ mice (n = 8 NP–PA; n = 9 NP–PA–bNeuGc). Sec-
ondary challenge was done on day 17. Because of the known weak TI-2 
responses in CD22/ mice, all conjugate injections were performed with 
a double dose of antigen (40 µg/mouse). (D) Responses in Siglecg/ mice 
(n = 8 NP–PA; n = 9 NP–PA–bNeuGc). Secondary challenge was done on 
day 18. Shown are means + SD. *, P < 0.05; **, P < 0.01; and ***, P < 0.005 
using the two-tailed Student’s t test.
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high affinity siglec ligands both reduce an immune response 
and facilitate induction of tolerance suggests possible uses in 
clinical settings in which induction of antigen-specific B cell 
tolerance might be beneficial. Further studies are required to 
define the optimal parameters of conjugates for efficacy in 
therapeutic tolerance induction.
The polymeric presentation of antigen and siglec ligands 
in this study is intended to mimic their simultaneous presen-
tation in a more biological context, such as a cell surface. 
Given the multivalency required for TI-2 responses, the ob-
servations made in this study might be highly relevant to B 
cell tolerance and response to high molecular weight self-
antigens in addition to cell surfaces. Siglec ligands may be espe-
cially important in restraining these responses because of their 
ubiquity and association with secreted and cell-surface pro-
teins. Cell surfaces should be particularly tolerogenic owing 
to the high number of self-moieties able to engage inhibitory 
receptors on B cells, such as siglecs, PirB, CD72, FcRIIb, 
BTLA, PD-1, and CD31, which recognize, respectively, 
sialic acids, MHC I, CD100, IgG-Fc, HVEM, PD-L1/2, and 
Although tolerance in the present study was induced by 
the native ligand with NeuGc, it is most efficiently induced 
using antigen conjugates carrying bNeuGc, which binds to 
both CD22 and Siglec-G with higher affinity. We attribute 
this to more efficient competition with cis ligands and re-
cruitment of siglecs to the site of antigen engagement with 
the BCR. As evident in the studies with B cells from the 
QM mice, the polymer containing both antigen and siglec 
ligands binds to B cells better than polymers containing ei-
ther one alone, demonstrating synergy in binding. In this re-
gard, Courtney et al. (2009) recently reported that a mouse 
2,4-dinitrophenol–specific B cell line suppressed early trig-
gering responses to 2,4-dinitrophenol when displayed on a 
polymer  backbone  with  NeuAc2-6Gal1-4Glc,  despite 
the fact that this glycan has low affinity for mouse CD22 
(<10% that of the preferred NeuGc ligand; Fig. 1 A; Blixt 
et al., 2003; Collins et al., 2006a). Thus, siglec ligands can 
produce graded responses of B cells depending on the affinity 
and degree of recruitment of siglec to the site of antigen en-
gagement.  Our  finding  that  copolymers  of  antigens  with 
Figure 5.  Effect of Ribi coadministration on tolerance induction and response to sialylated and unsialylated antigens. (A) Mice received the 
indicated conjugates in the presence or absence of Ribi; serum IgM and IgG3 anti-NP levels were measured on days 7 and 14. (B) Mice were treated with 
the tolerogenic compound NP–PA–bNeuGc with or without Ribi on day 0, and were rechallenged on day 18 with NP–PA. Shown are serum anti-NP titers 
monitored on day 25. Results are representative of three experiments. For all experimental groups, eight mice were analyzed. Shown are means + SD. All 
statistical tests given used the two-tailed Student’s t test. *, P < 0.05; ***, P < 0.005. n.s., not significant.JEM VOL. 207, January 18, 2010 
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ated  with  B  cell  proliferation,  a  block  in  plasma  cell 
differentiation, and lack of CD93 expression (unpublished 
data), features that distinguish tolerized B cells from conven-
tional anergic cells (Adams et al., 1990; Merrell et al., 2006). 
The time required for tolerance induction might in part be 
a function of a slow rate of antigen trafficking from the site 
of injection, but we noted splenic responses to peritoneal 
injection by 7 d. Tolerance induction by NP–PA–bNeuGc 
was inhibitable by Bcl2 expression in B cells, which did not 
permit direct response to the ligand but instead simply rescued 
heparin (Long, 2008). If tissues defend themselves through 
expression of self-markers, then cell type–specific heteroge-
neity or defects in that expression are predicted to contribute 
to tissue-specific autoimmune disease.
In the present study, ligands carrying bNeuGc moieties 
were not only nonimmunogenic in all contexts analyzed but 
usually promoted long-lived tolerance, preventing B cell re-
sponses to rechallenge with immunogenic conjugate. Mice 
deficient in CD22, Siglec-G, or both failed to respond. Tol-
erance developed slowly over several days and was associ-
Figure 6.  Flow cytometry and serum antibody analysis of in vivo responses of NP-specific B cells to sialylated and unsialylated conjugates. 
Rag1/ mice that received 107 isolated splenic QM transgenic B cells were challenged with 40 µg of the indicated conjugates 2 h later. From the time 
of reconstitution they were labeled with BrdU as indicated in Materials and methods. Similar results were obtained in two independent experiments 
similar in design but using CFSE-prelabeled B cells rather than BrdU to measure cell division (e.g., Fig. S4). (A) At day 7 after reconstitution, spleen cells 
were analyzed for BrdU uptake and B cell marker expression. A lymphocyte gate was used for analysis. Plots shown were representative of mice receiv-
ing NP–PA–bNeuGc (n = 5), NP–PA (n = 5), PA–bNeuGc (n = 3), and PBS (n = 3). Percentages are shown. (B) Quantitation of percentages of IgM+ plasma 
cells as defined by high levels of cytoplasmic IgM. (C) Percentages of B220+ cells scoring positive for BrdU uptake. (D) Serum anti-NP IgM and IgG3 anti-
body titers of the indicated recipients obtained at day 7 after reconstitution/challenge. Shown are means + SD. *, P < 0.05; and ***, P < 0.005 using the 
two-tailed Student’s t test. n.s., not significant.182 Missing self–recognition by B cells | Duong et al.
immunity  to  repetitive  ligands  when  second  signals  are 
still inadequate.
Though  they  failed  to  respond  directly  to  NP–PA–
bNeuGc, mice lacking CD22, Siglec-G, or both showed 
impaired  tolerance  induction,  as  revealed  by  rechallenge 
with NP–PA. In these mutants, IgG3 responses failed to 
recover but IgM responses were restored, indicating that in-
teraction with these siglecs contributed to the tolerance in-
duction in vivo. Why was only IgM and not IgG3 antibody 
restored by knockout of CD22 or Siglec-G? We presume 
that there is preferential rescue in the knockouts of those B cell 
clones with lower average affinity for NP, which might score 
well in the IgM assay but not in the IgG3 assay, or might fail 
to switch owing to this lower affinity. Because NP–PA–bNeuGc 
was  not  itself  immunogenic  even  in  CD22/;Siglecg/ 
mice, presumably its bNeuGc moiety interacts with other 
molecules besides CD22 and Siglec-G to effect tolerance 
and to suppress direct anti-NP responses. One possible can-
didate receptor is Siglec-E, which is expressed in marginal 
zone B cells (Zhang et al., 2004) and might be responsible for 
the residual binding of PA–bNeuGc to CD22/;Siglecg/  
B cells.
Although we cannot exclude that immunogenic conju-
gates somehow activate accessory cells in promoting TI-2 
antibody responses, we believe that our data show that si-
alylated conjugates work directly on B cells for the following 
reasons. Had the effect not been direct, but instead through 
antigen-nonspecific accessory cells, treatment of mice with 
sialylated conjugate lacking hapten would have reduced sub-
sequent responses to the haptenated conjugate (Fig. S1 A). 
Moreover, direct signaling and proliferation effects were seen 
in cultures of purified B cells. Finally, given its structure, it is 
difficult to imagine that a B cell could effectively contact 
NP–PA–bNeuGc conjugate without coengaging siglecs.
We suspect that there are deep evolutionary origins to 
the  siglec  receptor  function  we  have  investigated.  Siglecs 
have been suggested to play a role in self-recognition in the 
context of myeloid cell recognition, where they negatively 
regulate  phagocytosis  and  activation  (Varki  and  Angata, 
2006; Carlin et al., 2009b; Chen et al., 2009). Siglec-G was 
recently proposed to play a role in regulating the innate im-
mune responses of dendritic cells to liver injury through the 
recognition of the carbohydrate-rich molecule CD24 (Chen 
et al., 2009). Moreover, Siglec 7 is expressed on NK cells, 
where it appears to carry out classical inhibitory functions 
(Nicoll  et  al.,  2003).  These  observations,  combined  with 
ours in this study, support the notion that missing self–recog-
nition is a common ancestral mechanism of self-/nonself-
discrimination in leukocytes.
A feature predicted to be common to missing self–signaling 
is the potential of cis ligands to dampen recognition by inhibi-
tory receptors of self-markers in trans. Indeed, in NK cells, B 
cells, and likely many other leukocytes, loss of expression of 
putative self-markers, such as MHC I and sialic acids, leads to 
hyperreactivity as a consequence of a lack of tonic inhibitory 
signaling (for review see Held and Mariuzza, 2008). The ability 
the ability to respond to rechallenge by unsialylated com-
pound. Thus, the mode of tolerance observed is complex, 
regulated both by differentiative arrest preventing plasma 
cell formation and apoptosis. It is unlikely that the impaired 
tolerance induction observed in the Bcl2 Tg mice could be 
explained by their elevated total NP-specific B cell numbers, 
because tolerance was readily inducible in mice receiving 
QM B cells, which had an NP-specific precursor frequency 
many orders of magnitude over that of non-BCR–trans-
genic mice. The significant delay and antigen-specific B cell 
proliferation associated with tolerance induction might serve 
to prevent premature elimination of foreign antigen-specific 
B cells, permitting their rescue by antigen-linked second 
signals, such as TLR ligands or T cell help, should they be-
come available late in the response. Perhaps more impor-
tantly, unsialylated TI-2 antigens promote rapid antibody 
responses that can precede the development of second signals 
or even occur in their absence. In the context of a microbial 
infection,  such  responses  would  provide  early  adaptive 
Figure 7.  In vivo analysis of the effect of B cell–enforced Bcl2 
expression on tolerance induction with NP–PA–bNeuGc. Bcl2 Tg or 
nontransgenic littermates were challenged with NP–PA–bNeuGc on day 0, 
followed by rechallenge with NP–PA on day 17. Shown are IgM and IgG3 
antibody titers of sera obtained at day 7 after primary or secondary chal-
lenge. Transgenic and nontransgenic littermates were immunized and sera 
were taken in three independent, noncontemporaneous immunization 
experiments; these sera were analyzed together by ELISA. Note that one 
Bcl2 Tg mouse had an extremely high titer that is given on a different 
scale than the other data points. No statistically significant differences 
were seen between Bcl2 Tg and nontransgenic littermate responses to 
NP–PA only (Fig. S5). ***, P < 0.005 using the two-tailed Student’s t test. 
n.s., not significant.JEM VOL. 207, January 18, 2010 
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likely explains the rapid coevolution of siglec ligands and 
their receptors.
Our studies help to explain an uncomfortable exception 
to the two-signal model with respect to B cell tolerance. For 
antigens with many epitopes, like TI-2 antigens, the model 
does not hold unless they are associated with ligands for in-
hibitory receptors. Nor are our results consistent with the 
notion that antigen organization alone regulates the TI-2 re-
sponse (Dintzis et al., 1976; Bachmann et al., 1993). Rather, 
we see immune recognition of mature B cells in the context 
of an evolutionarily ancient leukocyte recognition system in 
which  self-markers  engaging  inhibitory  receptors  prevent 
self-reactivity, and in their absence a cell-autonomous, but 
perhaps self-limited, response is possible.
MATERIALS AND METHODS
Synthesis  of  sialosides,  PA–sialoside  conjugates,  and  NP–PA– 
sialoside conjugates. bNeuGc was prepared as previously described (Collins 
et al., 2006a). NeuGc and other glycans (Gal1-4GlcNAc–O-ethylazide, 
to more efficiently overcome competition with cis ligands 
probably explains the greater effectiveness, compared with 
natively sialylated compounds, of bNeuGc-containing conju-
gates in suppressing antibody responses and in the induction 
of tolerance.
Our results have implications for host defense and micro-
bial evasion. T-independent antibody responses can be rapid 
and elicit antibodies with complement-fixing ability impor-
tant in resistance to bacteria (Martin et al., 2001; Alugupalli 
et al., 2004). The ability to produce sialic acid–containing 
glycosylations is a specialization of pathogenic microbes that 
has been explained as a means to evade complement-mediated 
destruction through recruitment of the complement inhibitor 
factor H (Tomlinson et al., 1994; Ngampasutadol et al., 2008) 
or to evade recognition by myeloid cells (Varki and Angata, 
2006). Our results suggest an additional possibility, namely 
to dampen the TI-2 antibody response to microbial surface 
antigens. Selection against these microbial countermeasures 
Figure 8.  In vitro analysis of conjugate binding and response by NP-specific B cells. (A) Flow cytometry analysis of conjugate binding to isolated 
NP-specific B cells from QM transgenic mice. PA ligands used in this assay carried biotin tags along with the indicated carbohydrate and hapten moi-
eties. (B) Ca2+ mobilization response monitored by Fluo-4 dye fluorescence. (C) Analysis of proliferation induced by the indicated concentrations of anti-
gens by 3[H]thymidine uptake. Cells were harvested at 39 h of culture after a 15-h labeling period. Shown are means + SD. *, P < 0.05; and ***, P < 0.005 
using the two-tailed Student’s t test. (D–G) Western blot analysis of protein phosphorylation induced by the indicated conjugates. The arrow indicates 
the expected molecular weight of CD22 on the pTyr blot. The number of independent replicates of the experiments shown in the indicated sections were 
as follows: A, one; B, two; C, three; D, three; and E–G, one.184 Missing self–recognition by B cells | Duong et al.
ond experiment, QM B cells purified by CD4/CD43 negative selection 
(Miltenyi Biotec) were first resuspended at 1–2 × 107 cells/ml in 0.1% 
BSA in PBS, labeled with 1 µl of 5 mM CFSE per milliliter of cell suspen-
sion for 10 min at 37°C, washed two times with DMEM containing 10% 
FBS, and injected i.v. into B6Ly5a mice at 107 cells/mouse. As before, all 
mouse recipients subsequently received (i.p.) 40 µg of the respective TI-2 
antigen or PBS alone 2 h later. On day 7, total spleen cells were har-
vested, and fates of QM cells marked by the Ly5b allele were analyzed by 
flow cytometry.
Flow cytometric analyses of surface markers, antigen binding, Ca2+ 
flux, and BrdU uptake. Cell-surface marker stains for FACS analyses were 
performed using standard protocol. All of the following antibodies were used 
at 1:200 dilution in FACS buffer (HBSS containing 1% BSA, 2 mM EDTA, 
and 0.1% NaN3), with 2 × 106 cells/stain: FITC anti-IgMa (BD), PE anti-IgD 
(eBioscience), PE-Cy7 anti-CD23 (eBioscience), Alexa Fluor 647 anti-IgM 
(clone  M41),  Pacific  blue  anti-CD21  (BioLegend),  allophycocyanin-Cy7 
anti-B220  (BD),  and  PerCP-Cy5.5–conjugated  antibodies  used  in  dump 
channel (CD4, CD8, F4/80, and Gr-1; BioLegend). To quantitate TI-2 anti-
gen binding to QM cells, 106 spleen cells were incubated with 1 µg of the 
biotinylated PA antigen in a total volume of 200 µl of FACS buffer on ice for 
30 min. After a wash with 2 ml of FACS buffer at 4°C, cells were stained on 
ice with cocktail containing 0.25 µg streptavidin-PE (eBioscience) along with 
(1:200 dilution each) Alexa Fluor 647 anti-B220, PerCP-Cy5.5 anti-CD4, 
and PerCP-Cy5.5 anti-CD8 (all from BioLegend) in a final volume of 200 µl. 
Similarly, binding of primary C57BL/6 spleen cells to PA probes containing 
various siglec ligands was assessed as described but by using 0.125 µg of probe 
per 106 cells with 2 h of incubation on ice. To measure intracellular Ca2+ re-
sponses to TI-2 antigens, 8 × 106 QM spleen cells were preincubated with 
500 µl Fluo-4 reagent (Invitrogen), 5 µg Fc Block (clone 2.4G2), and 1 µg 
each of PerCP-Cy5.5–labeled CD4 and CD8 (BioLegend). Aliquots of 106 
cells were stimulated with 50 µg/ml of TI-2 antigen at room temperature. 
Ca2+ signals were recorded for 200 s, gating on CD4/CD8 double-negative 
cells. Flow cytometric analysis of BrdU incorporation was performed using 
the FITC BrdU Flow Kit (BD) according to the manufacturer’s instructions. 
All flow cytometric data were acquired on a FACSCalibur or LSR II (BD) 
and were analyzed using the FlowJo program (Tree Star, Inc.).
Western blotting and immunoprecipitation. B cells were purified from 
QM mouse spleens by CD4/CD43 negative selection (Miltenyi Biotec). Ali-
quots of 107 cells in 1 ml HBSS buffer, prewarmed to 37°C in a water bath, 
were stimulated with 25 µg of the respective TI-2 antigen for 5 or 30 min. 
Pelleted cells were lysed in 100 µl of lysis buffer consisting of TBS containing 
1% NP-40, Complete EDTA-Free Protease Inhibitor Cocktail (Roche), 
5 mM EDTA, 10 mM NaF, and 1 mM Na3VO4. For straight Western blotting 
analyses, 10 µl of each lysate after removing insoluble debris by centrifugation 
was run in 4–12% NuPAGE gels (Invitrogen). For CD22 immunoprecipita-
tion, each lysate of 107 cells/ml was precleared with 30 µl of streptavidin aga-
rose resin (Thermo Fisher Scientific) for 1 h at 4°C, and was then incubated 
with 5 µg of biotinylated Cy34.1 antibody (BD) overnight at 4°C. On the 
next day, 30 µl of the streptavidin agarose resin was added into each lysate, 
washed three times with lysis buffer, and incubated at 70°C for 10 min in 2× 
NuPAGE  loading  buffer  containing  100  mM  dithiothreitol  before  SDS-
PAGE. 0.2-µm nitrocellulose membranes (Bio-Rad Laboratories) were used 
for  all  Western  blotting  analyses.  Antiphosphotyrosine  (4G10)  and  anti-
GAPDH (6C5) antibodies, used at 1:1,000 and 1:10,000, respectively, diluted 
in TBS/T containing 5% milk, were purchased from Millipore. Polyclonal 
antibodies against SHP-1, phospho-CD19 (Tyr531), phospho-Akt (Ser473), 
and total Akt were purchased from Cell Signaling Technology and used ac-
cording to the manufacturer’s recommendations. Goat anti–mouse CD22 was 
used at 1:100 dilution in 5% milk in TBS/T (M-20; Santa Cruz Biotechnol-
ogy, Inc.). All HRP-conjugated secondary polyclonal antibodies, purchased 
from Jackson ImmunoResearch Laboratories, Inc., were used at 1:30,000 di-
luted in 5% milk in TBS/T. Signals were developed using the SuperSignal 
West Pico Chemiluminescent Substrate (Thermo Fisher Scientific). To strip 
NeuAc2-6Gal1-4GlcNAc–O-ethylazide,  and  NeuGc2-3Gal1-
4GlcNAc–O-ethylazide) were prepared as previously described (Blixt et al.,   
2003). Three PA–sialoside conjugates containing 20 mol% sialoside and 2.5% 
biotin (PA–NeuGc, PA–NeuGc2-3Gal1-4GlcNAc, and PA–NeuAc2-
3Gal1-4GlcNAc)  were  provided  by  the  Consortium  for  Functional 
Glycomics (http://www.functionalglycomics.org). Other PA conjugates 
were prepared as previously described (Bovin et al., 1993) by reducing 
the corresponding sialoside-azides to the respective sialoside-amines and 
coupling to PA (1,000 kD), resulting in a conjugate with 20 mol% si-
aloside and 2.5 mol% biotin. Similarly, NP–PA and NP–PA–sialoside im-
munogen PA conjugates (1,000 kD) were prepared with 10 mol% NP 
(NP-hexyl-amine) with 10 mol% NP and 20 mol% of the corresponding 
ethyl-amines of either Gal1-4GlcNAc, the bNeuGc trisaccharide, or the 
NeuGc trisaccharide.
Mice and TI-2 immunizations. C57BL/6J mice were obtained from ei-
ther the Jackson Laboratory or the Scripps Research Institute in-house breed-
ing program. CD22/ (provided by E. Clark [University of Washington, 
Seattle, WA] and L. Nitschke [University of Erlangen, Erlangen, Germany]; 
Otipoby et al., 1996), Siglecg/ (provided by Y. Liu, University of Michigan, 
Ann Arbor, MI; Ding et al., 2007), QM (provided by M. Cascalho, Univer-
sity of Michigan, Ann Arbor, MI; Cascalho et al., 1996), Bcl2 Tg (provided by 
A. Strasser and A. Harris, Walter and Eliza Hall Institute of Medical Research, 
Parkville, Australia; Strasser et al., 1991), Rag1/, and B6Ly5a (B6.SJL-Ptprca 
Pep3b/BoyJ; The Jackson Laboratory) mice have been previously described. All 
genetically modified mice were on a C57BL/6J background. CD22/;Siglecg/ 
mice were obtained by crossing the CD22/ and Siglecg/ mice and PCR 
screening for recombination of the two null alleles. All mice used in this study 
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